Medical network - on January 13, "Yi Rui sand" Chinese version coming!
▍ first copy is coming!
Yesterday (12), the national food administration of drug safety (CFDA) website, approved the treatment cancer drugs, AIDS in accordance with the non - the pills and fumaric acid tenofovir two pyrazole cefuroxime ester listed domestically produced generic drugs.
Three new counterpart of branded drugs for lung cancer treatment respectively global star "Yi Rui sand", anti-hiv drugs "much better" and hepatitis b drug viread, are first-line treatment drugs within their respective fields.
According to the CFDA yesterday's public information, the confirmation of qilu pharmaceutical co., LTD. (hainan) production the treatment of di, biological medicine, Shanghai co., LTD., production in accordance with the bate whalen, chengdu pharmaceutical co., LTD. Production of fumaric acid tenofovir two pyrazole cefuroxime ester were the first generic success of drugs, and the original the quality and efficacy of drugs.
Administration of state food and drug supervision and management of data query system show that as of January 2017, there were 50 companies in the treatment for generic; Nine generic drug firms application in accordance with the wayland, 49 companies applying to fumaric acid tenofovir two pyrazole cefuroxime ester.
Not only that, administration approved the corresponding domestic API listed at the same time, has realized from the API to the localization - war preparations.
▍ battle for market
M Intranet data show that in 2015 China used in cancer treatment, the total cost of $107 billion, up 11.5% from a year earlier. Antitumor drug market data analysis from 2015, monoclonal antibody drug occupied 36.92%, 27.84% standard chemotherapy drugs, small molecular targeted drugs accounted for 22.94%.
Under the rigid demand, in recent years, China's hospital drug use drugs to market shows a tendency of rapid growth, in 2015 major cities in our country public hospital lung cancer chemotherapy drug market has reached 6.509 billion yuan, year-on-year growth of 5.61% a year, conservative estimates China's lung cancer treatment market size of the market has reached 26 billion yuan.
Only Yi Rui sand, for example, generic channel will open the rapid change in the pattern of the existing market lung cancer treatment.
Public data shows that lung cancer incidence in China grew by 26.9% a year, lung cancer has become the first cause of death of malignancy, at present, our country each 1 in 4 cases of malignant tumor death cases of lung cancer patients, by 2025, will reach 1 million lung cancer patients in our country, to become the world's first lung cancer.
Diseases of the huge market, long-term clinical first-line treatment drugs Yi Rui sand become one of the most famous cancer treatment drug, even in cancer drugs act as purchasing agency industry chain is the source of India, Yi Rui sand is one of the hottest item bought.
Drugs act as purchasing agency website information from India, the British Yi Rui sand (IRESSA) is currently in the domestic price is about 5000 RMB 10, 250 mg per grain, according to a daily amount, monthly 15000; India Yi Rui sand sales price RMB 1500 ~ 1800, price six to one.
In the face of widespread public demand, on May 20, 2016, national health development planning commission released the first batch of national drug price negotiations to the society results: first-line treatment chronic hepatitis b drug tenofovir ester, non-small cell lung cancer targeted therapy drugs for ek, the treatment and the three drugs, a drop of 67%, 54%, 55%, the price of 490 yuan, 1399 yuan and 2358 yuan respectively.
And this time after let go of imitation, has a 55% cut Yi Rui viread sand and reduce our price by 67%, prices will fall further, the emergence of generic drugs will also was thoroughly involved in fighting and competition of the market.
The beginning of 2016, the CFDA for prevention and control of AIDS, diseases such as malignant tumor, major infectious diseases and rare diseases of innovative medicine and drug approval for priority review, such as urgent clinical needs.
By the end of December 2016, has published 12 batches of drug priority review directory of examination and approval, involving 191 applications for registration, and will continue to increase in subsequent has significant clinical value, treatment of major diseases such as HIV/AIDS drug research and development support to declare, encourage drug innovation, improving the quality of medicines. |
